PHARMING GROUP NV (PHARM.AS) Stock Fundamental Analysis

Europe • Euronext Amsterdam • AMS:PHARM • NL0010391025

1.366 EUR
-0.01 (-0.8%)
Last: Feb 10, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

5

PHARM gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 81 industry peers in the Biotechnology industry. Both the profitability and the financial health of PHARM get a neutral evaluation. Nothing too spectacular is happening here. PHARM is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • PHARM had negative earnings in the past year.
  • PHARM had a positive operating cash flow in the past year.
  • In multiple years PHARM reported negative net income over the last 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: PHARM reported negative operating cash flow in multiple years.
PHARM.AS Yearly Net Income VS EBIT VS OCF VS FCFPHARM.AS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

  • With a decent Return On Assets value of 0.08%, PHARM is doing good in the industry, outperforming 70.37% of the companies in the same industry.
  • With a decent Return On Equity value of 0.14%, PHARM is doing good in the industry, outperforming 74.07% of the companies in the same industry.
  • PHARM's Return On Invested Capital of 7.08% is amongst the best of the industry. PHARM outperforms 83.95% of its industry peers.
Industry RankSector Rank
ROA 0.08%
ROE 0.14%
ROIC 7.08%
ROA(3y)-0.68%
ROA(5y)2.2%
ROE(3y)-1.17%
ROE(5y)5.07%
ROIC(3y)N/A
ROIC(5y)N/A
PHARM.AS Yearly ROA, ROE, ROICPHARM.AS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

  • PHARM has a Profit Margin of 0.11%. This is in the better half of the industry: PHARM outperforms 71.60% of its industry peers.
  • PHARM's Operating Margin of 10.06% is fine compared to the rest of the industry. PHARM outperforms 79.01% of its industry peers.
  • PHARM has a Gross Margin of 89.90%. This is amongst the best in the industry. PHARM outperforms 83.95% of its industry peers.
  • In the last couple of years the Gross Margin of PHARM has remained more or less at the same level.
Industry RankSector Rank
OM 10.06%
PM (TTM) 0.11%
GM 89.9%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.48%
GM growth 5Y0.17%
PHARM.AS Yearly Profit, Operating, Gross MarginsPHARM.AS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), PHARM is creating some value.
  • PHARM has more shares outstanding than it did 1 year ago.
  • PHARM has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for PHARM has been reduced compared to a year ago.
PHARM.AS Yearly Shares OutstandingPHARM.AS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
PHARM.AS Yearly Total Debt VS Total AssetsPHARM.AS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • PHARM has an Altman-Z score of 1.08. This is a bad value and indicates that PHARM is not financially healthy and even has some risk of bankruptcy.
  • PHARM has a better Altman-Z score (1.08) than 60.49% of its industry peers.
  • PHARM has a debt to FCF ratio of 2.49. This is a good value and a sign of high solvency as PHARM would need 2.49 years to pay back of all of its debts.
  • PHARM has a better Debt to FCF ratio (2.49) than 85.19% of its industry peers.
  • PHARM has a Debt/Equity ratio of 0.46. This is a healthy value indicating a solid balance between debt and equity.
  • PHARM has a Debt to Equity ratio of 0.46. This is comparable to the rest of the industry: PHARM outperforms 54.32% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF 2.49
Altman-Z 1.08
ROIC/WACC1.22
WACC5.8%
PHARM.AS Yearly LT Debt VS Equity VS FCFPHARM.AS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

  • PHARM has a Current Ratio of 3.16. This indicates that PHARM is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of PHARM (3.16) is better than 64.20% of its industry peers.
  • PHARM has a Quick Ratio of 2.39. This indicates that PHARM is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 2.39, PHARM perfoms like the industry average, outperforming 55.56% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.16
Quick Ratio 2.39
PHARM.AS Yearly Current Assets VS Current LiabilitesPHARM.AS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 96.30% over the past year.
  • PHARM shows a strong growth in Revenue. In the last year, the Revenue has grown by 26.78%.
  • The Revenue has been growing by 10.64% on average over the past years. This is quite good.
EPS 1Y (TTM)96.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%600%
Revenue 1Y (TTM)26.78%
Revenue growth 3Y14.33%
Revenue growth 5Y10.64%
Sales Q2Q%30%

3.2 Future

  • PHARM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 53.48% yearly.
  • Based on estimates for the next years, PHARM will show a quite strong growth in Revenue. The Revenue will grow by 8.97% on average per year.
EPS Next Y111.44%
EPS Next 2Y85.83%
EPS Next 3Y65.17%
EPS Next 5Y53.48%
Revenue Next Year26.31%
Revenue Next 2Y14.87%
Revenue Next 3Y10.89%
Revenue Next 5Y8.97%

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
PHARM.AS Yearly Revenue VS EstimatesPHARM.AS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M 500M
PHARM.AS Yearly EPS VS EstimatesPHARM.AS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.1 -0.1 0.2

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Forward Earnings ratio of 62.06 indicates a quite expensive valuation of PHARM.
  • Based on the Price/Forward Earnings ratio, PHARM is valued a bit cheaper than 71.60% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 27.97. PHARM is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 62.06
PHARM.AS Price Earnings VS Forward Price EarningsPHARM.AS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • 97.53% of the companies in the same industry are more expensive than PHARM, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, PHARM is valued cheaper than 98.77% of the companies in the same industry.
Industry RankSector Rank
P/FCF 2.15
EV/EBITDA 0.86
PHARM.AS Per share dataPHARM.AS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4

4.3 Compensation for Growth

  • PHARM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as PHARM's earnings are expected to grow with 65.17% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y85.83%
EPS Next 3Y65.17%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • PHARM does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PHARMING GROUP NV

AMS:PHARM (2/10/2026, 7:00:00 PM)

1.366

-0.01 (-0.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)03-11
Inst Owners21.51%
Inst Owner ChangeN/A
Ins Owners1.39%
Ins Owner ChangeN/A
Market Cap95.17M
Revenue(TTM)362.27M
Net Income(TTM)383.00K
Analysts88.57
Price Target2.19 (60.32%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)597.09%
Min EPS beat(2)123.3%
Max EPS beat(2)1070.87%
EPS beat(4)2
Avg EPS beat(4)281.14%
Min EPS beat(4)-42.39%
Max EPS beat(4)1070.87%
EPS beat(8)3
Avg EPS beat(8)65.03%
EPS beat(12)5
Avg EPS beat(12)12.9%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)4.89%
Min Revenue beat(2)1.11%
Max Revenue beat(2)8.68%
Revenue beat(4)4
Avg Revenue beat(4)8.65%
Min Revenue beat(4)1.11%
Max Revenue beat(4)13.37%
Revenue beat(8)5
Avg Revenue beat(8)1.62%
Revenue beat(12)7
Avg Revenue beat(12)-0.52%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.88%
PT rev (3m)12.57%
EPS NQ rev (1m)40.1%
EPS NQ rev (3m)294.5%
EPS NY rev (1m)-91.51%
EPS NY rev (3m)-91.06%
Revenue NQ rev (1m)1.64%
Revenue NQ rev (3m)9.47%
Revenue NY rev (1m)0%
Revenue NY rev (3m)6.36%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 62.06
P/S 0.31
P/FCF 2.15
P/OCF 2.13
P/B 0.43
P/tB 0.87
EV/EBITDA 0.86
EPS(TTM)0
EYN/A
EPS(NY)0.02
Fwd EY1.61%
FCF(TTM)0.63
FCFY46.48%
OCF(TTM)0.64
OCFY47.03%
SpS4.37
BVpS3.2
TBVpS1.57
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 0.08%
ROE 0.14%
ROCE 9.44%
ROIC 7.08%
ROICexc 12.44%
ROICexgc 32.23%
OM 10.06%
PM (TTM) 0.11%
GM 89.9%
FCFM 14.51%
ROA(3y)-0.68%
ROA(5y)2.2%
ROE(3y)-1.17%
ROE(5y)5.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.48%
GM growth 5Y0.17%
F-Score7
Asset Turnover0.76
Health
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF 2.49
Debt/EBITDA 2.33
Cap/Depr 4%
Cap/Sales 0.17%
Interest Coverage 5.94
Cash Conversion 102.18%
Profit Quality 13727.2%
Current Ratio 3.16
Quick Ratio 2.39
Altman-Z 1.08
F-Score7
WACC5.8%
ROIC/WACC1.22
Cap/Depr(3y)9.71%
Cap/Depr(5y)59.68%
Cap/Sales(3y)0.61%
Cap/Sales(5y)3.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)96.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%600%
EPS Next Y111.44%
EPS Next 2Y85.83%
EPS Next 3Y65.17%
EPS Next 5Y53.48%
Revenue 1Y (TTM)26.78%
Revenue growth 3Y14.33%
Revenue growth 5Y10.64%
Sales Q2Q%30%
Revenue Next Year26.31%
Revenue Next 2Y14.87%
Revenue Next 3Y10.89%
Revenue Next 5Y8.97%
EBIT growth 1Y355.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year401.72%
EBIT Next 3Y93.29%
EBIT Next 5Y78.86%
FCF growth 1Y309.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y325.01%
OCF growth 3YN/A
OCF growth 5YN/A

PHARMING GROUP NV / PHARM.AS FAQ

What is the ChartMill fundamental rating of PHARMING GROUP NV (PHARM.AS) stock?

ChartMill assigns a fundamental rating of 5 / 10 to PHARM.AS.


What is the valuation status for PHARM stock?

ChartMill assigns a valuation rating of 5 / 10 to PHARMING GROUP NV (PHARM.AS). This can be considered as Fairly Valued.


Can you provide the profitability details for PHARMING GROUP NV?

PHARMING GROUP NV (PHARM.AS) has a profitability rating of 5 / 10.